NCT03063619: Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast |
|
|
| Completed | 2 | 194 | US | Afimoxifene, 4-Hydroxy-Tamoxifen, 4-Hydroxytamoxifen, 4-OHT, Laboratory Biomarker Analysis, Placebo, placebo therapy, PLCB, sham therapy, Questionnaire Administration | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Mammographically Dense Breast | 10/21 | 10/21 | | |
NCT01471106: Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer |
|
|
| Active, not recruiting | 2 | 26 | US | Dasatinib, BMS-354825, Sprycel | M.D. Anderson Cancer Center, Susan G. Komen Breast Cancer Foundation, Bristol-Myers Squibb | Breast Cancer | 01/25 | 01/25 | | |
NCI-2019-04148, NCT04090567: Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer |
|
|
| Recruiting | 2 | 60 | US | Cediranib, AZD2171, Ceralasertib, AZD6738, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281 | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8 | 03/25 | 03/25 | | |
NCT05126810: Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling |
|
|
| Recruiting | N/A | 500 | US | Questionnaire Administration | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Li-Fraumeni Syndrome | 02/27 | 10/27 | | |
NCT05694559: Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics |
|
|
| Recruiting | N/A | 1000 | US | Genetic Testing and Counseling, Screening Form | M.D. Anderson Cancer Center | Breast Cancer, Colorectal Cancer | 02/27 | 02/27 | | |
